

Aqua Fem Media Kit

About Aqua Fem

Aqua Fem, LLC is a biotechnology company pioneering marine biomedical innovations to address one of the most urgent and underserved challenges in healthcare: infertility. Headquartered in Charleston, South Carolina, Aqua Fem was founded to advance affordable and accessible fertility solutions rooted in rigorous science.

At the center of this mission is AF, a patented, marine-derived compound proven to significantly increase sperm motility — one of the most critical factors in conception. Designed for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intrauterine insemination (IUI), AF also has potential as an over-the-counter option for couples trying to conceive naturally.

Aqua Fem's leadership team brings together expertise in reproductive science, marine biomedicine, business innovation and healthcare marketing. Together, they are committed to unlocking new pathways for fertility treatment and ensuring that solutions are both effective and widely accessible.

Fast Facts

- **Founded:** 2014
 - **Headquarters:** Charleston, SC
 - **Innovation:** AF – novel sperm motility-enhancing compound
 - **Patent:** Full filing Spring 2026, pipeline-ready IP asset
 - **Target Applications:**
 - Assisted Reproductive Technologies (IVF, IUI, ICSI)
 - Consumer fertility (at-home, OTC)
 - Diagnostics & Research (sperm function assays, fertility testing)
 - **Opportunity:** Currently seeking strategic buyers for full acquisition of AF IP
-

Key Messages

- Male infertility accounts for ~50% of infertility cases, yet treatment innovation lags far behind female fertility.
 - Sperm motility is one of the strongest predictors of success in IVF and IUI outcomes.
 - AF represents a first-in-class solution with broad applications across ART labs, consumer fertility products, and fertility diagnostics.
 - Aqua Fem is not commercializing directly—we are offering AF for full acquisition to industry leaders ready to accelerate its clinical and market potential.
-

Founders

Roderick Duell – Founder & Chief Executive Officer

ceo@aquafemlabs.com

A serial entrepreneur with deep experience in business development and commercialization, Rod brings vision and operational leadership to Aqua Fem. He specializes in early-stage venture strategy and commercialization of emerging technologies. As CEO, he leads partnerships, IP transactions, and strategic growth..

Eric Lacy – Founder & Chief Scientific Officer

csso@aquafemlabs.com


A cell biologist and marine biomedical researcher, Eric is the scientific architect behind Aqua Fem, exploring fertility using marine model systems. Eric's work has uncovered novel biological pathways that underpin the development of AF — Aqua Fem's lead innovation. At Aqua Fem, he directs R&D, study design, and scientific positioning of the IP.

Media Assets

- Logo

AQUA FEM

- **Headshots for Roderick Duell and Eric Lacy**



- **AF Overview**

IP FOR SALE: SCALABLE SOLUTION TO A CRITICAL, UNDERSERVED NEED IN A \$39B MARKET

AF: A Novel Compound to Boost Sperm Motility

A breakthrough opportunity in male fertility with global market potential

What is AF?

AF is a proprietary compound that instantly increases sperm motility on contact through a novel mechanism of action.

Potential applications include:

- **Consumer Fertility**
As an OTC enhancement for men; potential for lubricants and at-home kits.
- **Assisted Reproductive Technologies (ART)**
As an additive to sperm washing media.



1.

Why AF Matters Now

AF is a critical innovation in an underserved male fertility market—with global fertility projected to reach **\$41 billion** by 2028.

2.

The Opportunity for Buyers

Acquire IP for a scalable, first-in-class solution with broad applications and no existing competing products addressing sperm motility.

3.

What You'll Get

Full rights to the AF asset, positioned for development, including IP (utility patent to issue 2026), proprietary know-how, and supporting data.

Interested in Learning More?

Aqua Fem is not seeking to commercialize AF directly. We're in search of a buyer positioned to take AF to market. To request more information or to setup an introductory call, please contact us at cco@aquafemlabs.com.

aquafemlabs.com

AQUA FEM



Frequently Asked Questions (FAQs)

Q1: What is AF?

AF is Aqua Fem's patented, marine-derived compound designed to significantly increase sperm motility — one of the most important predictors of fertilization success. It is the first fertility innovation of its kind with reproducible, independent clinic data showing dramatic improvements in motility.

Q2: Why is sperm motility so important?

Sperm motility measures a sperm cell's ability to swim effectively toward an egg. In both natural conception and assisted reproductive technologies (ART), motility is one of the strongest predictors of fertilization success. Low motility is a major barrier to conception, and existing interventions have limited impact.

Q3: What makes AF different from other fertility supplements or lab media?

Unlike most over-the-counter fertility supplements, AF's efficacy is supported by independent clinical data. In a recent study, AF increased sperm motility by 200%, 212%, and 600% across multiple donors and timepoints, building on prior results showing ~700% average increases. These findings confirm both reproducibility and reliability. AF is also being developed specifically for integration into sperm preparation media, making it directly applicable in IVF and IUI.

Q4: How does AF work?

AF's patented hetero-dimeric form enhances sperm motility through a novel, marine-derived mechanism. While the precise molecular interactions are proprietary, AF's unique structure differentiates it from existing ART media additives or consumer supplements, making it a first-in-class innovation.

Q5: Is AF safe and clinically viable?

Yes. AF was designed to be compatible with existing ART workflows and is being evaluated for use in sperm preparation media. Early studies have shown strong safety and reproducibility profiles, supporting its potential for both clinical and at-home applications.

Q6: Why is Aqua Fem selling the AF IP rather than commercializing it directly?

Aqua Fem's mission is to pioneer fertility innovation and bring proven, science-driven solutions to patients worldwide. By offering AF for full acquisition, Aqua Fem aims to partner with an established fertility, biotech, or consumer health company that can accelerate development, secure regulatory approvals, and bring the product to market on a global scale.

Q7: Who would benefit most from AF?

- **Fertility clinics and ART labs:** Integration into sperm preparation media can enhance motility, improving fertilization rates and overall IVF/IUI success.
 - **Couples trying to conceive naturally:** AF's potential as an over-the-counter product offers an affordable, accessible option in a space where few scientifically validated solutions exist.
 - **Diagnostics & Research:** AF may provide a new tool for sperm function assays and fertility testing, giving researchers and clinicians a more sensitive and reproducible way to evaluate sperm quality.
 - **Industry leaders:** AF represents a rare opportunity to acquire a pipeline-ready, patent-protected innovation that addresses one of the largest unmet needs in reproductive medicine.
-

Q8: What is the next step for interested buyers or partners?

Aqua Fem is currently seeking a strategic buyer for the full AF IP portfolio. Interested parties can contact Aqua Fem's business development team at cco@aquafemlabs.com to begin discussions.

Contact

Media Inquiries

Kara DeMaio

Chief Communications Officer

Aqua Fem, LLC

cco@aquafemlabs.com